SCHEMBL23525604

SCHEMBL23525604

N#CC(=C1Nc2ccccc2C1=O)c1c[nH]c2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IMPDH2 P12268 1/20 0.43
▸ IMPDH1 P20839 1/20 0.43
▸ GPR84 Q9NQS5 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ AHR P35869 1/20 0.42
▸ NTRK1 P04629 2/20 0.41
▸ DAPK3 O43293 1/20 0.41
▸ PRKD3 O94806 1/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ LCK P06239 1/20 0.41
▸ FYN P06241 1/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ RET P07949 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10466726 0.69 GPR84 (0.65) IMPDH2IMPDH1GPR84ALDH1A1MEN1
SCHEMBL5469781 0.68 PBRM1 (0.51) GPR84ALDH1A1LMNAMAPTKMT2A
SCHEMBL24651224 0.66 GPR84 (0.61) GPR84ALDH1A1MEN1MAPTKMT2A
SCHEMBL5813081 0.66 NTRK1 (0.48) GPR84ALDH1A1TDP1NTRK1DAPK3
SCHEMBL5822163 0.66 NTRK1 (0.48) GPR84ALDH1A1NTRK1DAPK3PRKD3
SCHEMBL27872853 0.66 GPR84 (0.55) IMPDH2IMPDH1GPR84ALDH1A1MEN1
SCHEMBL5468659 0.65 NTRK1 (0.47) GPR84MEN1MAPTKMT2ANTRK1
SCHEMBL8336309 0.65 GPR84 (0.53) IMPDH2IMPDH1GPR84ALDH1A1MEN1
SCHEMBL17207498 0.64 KIF20A (0.65) IMPDH2IMPDH1GPR84ALDH1A1MEN1
SCHEMBL26070596 0.64 ALDH1A1 (0.57) IMPDH2IMPDH1GPR84ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240293366-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AZORA THERAPEUTICS, INC. 2024-09-05 — — US disclosed
EP-4252844-A2 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AZORA THERAPEUTICS, INC. (US) 2023-10-04 — — EP disclosed
CN-114206312-A Topical compositions and methods for treating inflammatory skin disorders 阿佐拉治疗股份有限公司 2022-03-18 — — CN disclosed
US-20220023259-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AZORA THERAPEUTICS, INC. 2022-01-27 — — US disclosed
US-11154533-B2 Topical compositions and methods for treating inflammatory skin diseases AZORA THERAPEUTICS, INC. (US) 2021-10-26 — — US disclosed
US-20210186931-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AZORA THERAPEUTICS, INC. 2021-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186931-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AHR, ARNT, TLR8 IMPDH2 439/4885IMPDH1 394/4885GPR84 148/4885
US-11154533-B2 Topical compositions and methods for treating inflammatory skin diseases AHR, ARNT, TLR8 IMPDH2 439/4885IMPDH1 394/4885GPR84 148/4885
US-20240293366-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AHR, ARNT, TLR8 IMPDH2 439/4885IMPDH1 394/4885GPR84 148/4885
US-20220023259-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AHR, ARNT, TLR8 IMPDH2 439/4885IMPDH1 394/4885GPR84 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback